NeoGenomics [NEO] vs Danaher [DHR] Detailed Stock Comparison
NeoGenomics
NASDAQ
Loading...
Danaher
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: NeoGenomics wins in 5 metrics, Danaher wins in 13 metrics, with 0 ties. Danaher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | NeoGenomics | Danaher | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -12.84 | 40.35 | NeoGenomics |
| Price-to-Book Ratio | 1.20 | 2.60 | NeoGenomics |
| Debt-to-Equity Ratio | 48.21 | 35.45 | Danaher |
| PEG Ratio | -0.10 | -1.08 | Danaher |
| EV/EBITDA | -164.14 | 20.17 | NeoGenomics |
| Profit Margin (TTM) | -15.10% | 14.21% | Danaher |
| Operating Margin (TTM) | -15.43% | 20.12% | Danaher |
| EBITDA Margin (TTM) | N/A | 20.12% | N/A |
| Return on Equity | -11.76% | 6.68% | Danaher |
| Return on Assets (TTM) | -3.25% | 4.01% | Danaher |
| Free Cash Flow (TTM) | $-34.04M | $5.30B | Danaher |
| 1-Year Return | -51.46% | -30.70% | Danaher |
| Price-to-Sales Ratio (TTM) | 1.49 | 5.67 | NeoGenomics |
| Enterprise Value | $1.28B | $151.69B | Danaher |
| EV/Revenue Ratio | 1.85 | 6.32 | NeoGenomics |
| Gross Profit Margin (TTM) | 42.61% | 59.35% | Danaher |
| Revenue per Share (TTM) | $5 | $33 | Danaher |
| Earnings per Share (Diluted) | $-0.82 | $4.71 | Danaher |
| Beta (Stock Volatility) | 1.62 | 0.78 | Danaher |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
NeoGenomics vs Danaher Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| NeoGenomics | -4.56% | -0.25% | 30.92% | 7.71% | -22.19% | -51.73% |
| Danaher | -2.62% | -5.07% | -7.62% | -7.34% | -7.27% | -17.30% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| NeoGenomics | -51.46% | -20.16% | -77.78% | 12.27% | 643.93% | 2,387.50% |
| Danaher | -30.70% | -22.62% | 3.91% | 228.01% | 593.36% | 983.52% |
News Based Sentiment: NeoGenomics vs Danaher
NeoGenomics
News based Sentiment: MIXED
NeoGenomics experienced a volatile month with a major legal victory offset by disappointing financial results and a securities fraud investigation. While the patent win is a positive catalyst, the financial concerns and investigation create significant uncertainty, making this a mixed story for investors.
Danaher
News based Sentiment: MIXED
September presented a mixed bag for Danaher, with positive analyst sentiment and shareholder-friendly actions countered by declining profits, regulatory concerns, and a continuing legal investigation. The combination of these factors makes this a significant month for investors to assess the company's trajectory.
Performance & Financial Health Analysis: NeoGenomics vs Danaher
| Metric | NEO | DHR |
|---|---|---|
| Market Information | ||
| Market Cap | $1.03B | $136.09B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 3,688,010 | 3,403,000 |
| 90 Day Avg. Volume | 2,608,390 | 3,347,127 |
| Last Close | $7.96 | $190.05 |
| 52 Week Range | $4.72 - $19.11 | $171.00 - $279.90 |
| % from 52W High | -58.35% | -32.10% |
| All-Time High | $61.57 (Feb 15, 2021) | $296.06 (Sep 06, 2021) |
| % from All-Time High | -87.07% | -35.81% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.10% | 0.03% |
| Quarterly Earnings Growth | 0.10% | -0.39% |
| Financial Health | ||
| Profit Margin (TTM) | -0.15% | 0.14% |
| Operating Margin (TTM) | -0.15% | 0.20% |
| Return on Equity (TTM) | -0.12% | 0.07% |
| Debt to Equity (MRQ) | 48.21 | 35.45 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.64 | $73.10 |
| Cash per Share (MRQ) | $1.27 | $4.13 |
| Operating Cash Flow (TTM) | $14.05M | $6.17B |
| Levered Free Cash Flow (TTM) | $4.77M | $3.88B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: NeoGenomics vs Danaher
| Metric | NEO | DHR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -12.84 | 40.35 |
| Forward P/E | 39.80 | 22.68 |
| PEG Ratio | -0.10 | -1.08 |
| Price to Sales (TTM) | 1.49 | 5.67 |
| Price to Book (MRQ) | 1.20 | 2.60 |
| Market Capitalization | ||
| Market Capitalization | $1.03B | $136.09B |
| Enterprise Value | $1.28B | $151.69B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.85 | 6.32 |
| Enterprise to EBITDA | -164.14 | 20.17 |
| Risk & Other Metrics | ||
| Beta | 1.62 | 0.78 |
| Book Value per Share (MRQ) | $6.64 | $73.10 |
Financial Statements Comparison: NeoGenomics vs Danaher
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NEO | DHR |
|---|---|---|
| Revenue/Sales | $168.04M | $5.74B |
| Cost of Goods Sold | $94.79M | $2.23B |
| Gross Profit | $73.25M | $3.51B |
| Research & Development | $10.18M | $379.00M |
| Operating Income (EBIT) | $-27.83M | $1.27B |
| EBITDA | $-6.31M | $1.87B |
| Pre-Tax Income | $-25.66M | $1.13B |
| Income Tax | $266,000 | $175.00M |
| Net Income (Profit) | $-25.92M | $954.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NEO | DHR |
|---|---|---|
| Cash & Equivalents | $346.19M | $1.99B |
| Total Current Assets | $573.93M | $9.53B |
| Total Current Liabilities | $279.70M | $6.65B |
| Long-Term Debt | $400.58M | $15.98B |
| Total Shareholders Equity | $888.27M | $50.86B |
| Retained Earnings | $-351.70M | $44.91B |
| Property, Plant & Equipment | $366.10M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NEO | DHR |
|---|---|---|
| Operating Cash Flow | $735,000 | $1.47B |
| Capital Expenditures | $-4.50M | $-239.00M |
| Free Cash Flow | $-29.83M | $1.05B |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-1.08B |
Short Interest & Institutional Ownership Analysis
| Metric | NEO | DHR |
|---|---|---|
| Shares Short | 5.23M | 9.55M |
| Short Ratio | 1.67 | 2.69 |
| Short % of Float | 0.06% | 0.02% |
| Average Daily Volume (10 Day) | 3,688,010 | 3,403,000 |
| Average Daily Volume (90 Day) | 2,608,390 | 3,347,127 |
| Shares Outstanding | 128.15M | 719.10M |
| Float Shares | 119.99M | 637.13M |
| % Held by Insiders | 0.01% | 0.11% |
| % Held by Institutions | 1.00% | 0.83% |
Dividend Analysis & Yield Comparison: NeoGenomics vs Danaher
| Metric | NEO | DHR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |